Unthinkable? Reports That AZ May Spin Off China Ops Amid Geopolitical Risks
Competing Pressures, Deeper Localization
AstraZeneca is reportedly considering joining a prominent investment fund to spin off and list its Chinese entities, in an apparent bid to better insulate them against potential geopolitical risks.
You may also be interested in...
Amid multinationals' accelerating de-risking and divestment moves in China, the country’s State Council has issued revised policies in the biologics manufacturing and gene therapy area, in a bid to attract foreign investment to the sector. But timely and consistent implementation will be key, an EU trade group says.
The company exceeded revenue and profit expectations in Q2, but sought to calm concerns about a rumored China spin-out and underwhelming Phase III data.
Plus deals involving ASLAN/Zenyaku Kogyo, AstraZeneca/Cholsegen, Astellas/Cullgen, AbCellera/Confo, Blue Water/WraSer, Solve/Cereius, Prime Medicine/Cimeio, Evox/Codiak, PharmaTher/Vitruvias and Adverum/Ray.